New 9-Valent HPV vaccine aims to shield chinese women from more Cancer-Causing strains

NCT ID NCT03998254

Ongoing Prevention Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 study tests a 9-valent HPV vaccine (V503) in 6,000 Chinese women aged 20-45 to see if it prevents persistent infection and cervical disease from five additional HPV types compared to the current 4-valent vaccine. Participants receive either the new vaccine or Gardasil, and researchers track infections, immune response, and side effects over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 9-valent HPV vaccine (V503)
What this could lead to: If successful, this vaccine could prevent infections and cervical precancers caused by nine HPV types in Chinese women.
What could go wrong: This is a late-stage trial, but results may not apply to all populations. Side effects like injection-site pain or fever are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PAPILLOMAVIRUS INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

human papilloma virus infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PAPILLOMAVIRUS INFECTIONS

Contacts and locations

Locations

Lingchuan Center for Disease Control and Prevention ( Site 0002)

Guilin, Guangxi, 541200, China
Mianyang Center for Disease Control and Prevention ( Site 0005)

Mianyang, Sichuan, 621000, China
Quanzhou Center for Disease Control and Prevention ( Site 0001)

Guilin, Guangxi, 541500, China
Santai County Center for Disease Control and Prevention ( Site 0006)

Mianyang, Sichuan, 621100, China
Xiangyuan Center for Disease Control and Prevention ( Site 0003)

Changzhi, Shanxi, 046299, China
Yanhu Center for Disease Control and Prevention of Yuncheng ( Site 0004)

Yuncheng, Shanxi, 044000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.